Reactive Arthritis after Intravesical Bacillus Calmette-Guérin Therapy

3Citations
Citations of this article
16Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Reactive arthritis (ReA) is a sterile arthritis that occurs in genetically predisposed individuals secondary to an extra-articular infection, usually of the gastrointestinal or genitourinary tract. Sterile arthritis associated with instillation of intravesical bacillus Calmette-Guérin (iBCG) therapy used for bladder cancer can also be included under ReA based on the pathogenic mechanism. Similar to spondyloarthritis, HLA-B27 positivity is a known contributor to the genetic susceptibility underlying iBCG-associated ReA. Other genetic factors, such as HLA-B39 and HLA-B51, especially in Japanese patients, can also be involved in the pathophysiology of iBCG-associated ReA. The frequencies of ReA- and ReA-related symptoms are slightly different between Japanese and Western studies. Proper understanding of possible complications, their epidemiology and pathogenesis, and their management is important for the rheumatologist when noting symptomatic patients using iBCG. Herein, we will review the most current information on ReA after iBCG therapy.

Cite

CITATION STYLE

APA

Taniguchi, Y., Nishikawa, H., Kimata, T., Yoshinaga, Y., Kobayashi, S., & Terada, Y. (2022, March 1). Reactive Arthritis after Intravesical Bacillus Calmette-Guérin Therapy. Journal of Clinical Rheumatology. Lippincott Williams and Wilkins. https://doi.org/10.1097/RHU.0000000000001768

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free